{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T20:15:05Z","timestamp":1783196105129,"version":"3.54.6"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004608","name":"Natural Science Foundation of Jiangsu Province","doi-asserted-by":"publisher","award":["22KJB210009"],"award-info":[{"award-number":["22KJB210009"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["32202334"],"award-info":[{"award-number":["32202334"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["JCYJ2412"],"award-info":[{"award-number":["JCYJ2412"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["LYG20230001"],"award-info":[{"award-number":["LYG20230001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019042","name":"Jiangsu Ocean University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100019042","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.bmc.2026.118730","type":"journal-article","created":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T14:30:50Z","timestamp":1780842650000},"page":"118730","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Novel (Z)-3-(2-(quinazolin-4-yloxy)phenyl)acrylates as potential EGFR inhibitors deriving from the renovation of coumarin skeletons: Design, synthesis, characterization and antineoplastic activity"],"prefix":"10.1016","volume":"140","author":[{"given":"Ruiying","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaona","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huajian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingyi","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxin","family":"Si","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaobin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmc.2026.118730_bb0005","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/s41392-024-01848-7","article-title":"Tumor initiation and early tumorigenesis: molecular mechanisms and interventional targets","volume":"9","author":"Zhang","year":"2024","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.bmc.2026.118730_bb0010","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1158\/2159-8290.CD-24-1379","article-title":"Long-term latency of highly mutated cells in normal mouse skin is reversed by exposure to tumor promoters and chronic tissue damage","volume":"15","author":"Li","year":"2025","journal-title":"Cancer Discov"},{"key":"10.1016\/j.bmc.2026.118730_bb0015","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1016\/j.cell.2023.03.028","article-title":"Cachexia: a systemic consequence of progressive, unresolved disease","volume":"186","author":"Ferrer","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.bmc.2026.118730_bb0020","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1038\/s42255-024-01167-9","article-title":"Cancer cachexia: multilevel metabolic dysfunction","volume":"6","author":"Berriel-Diaz","year":"2024","journal-title":"Nat Metab"},{"key":"10.1016\/j.bmc.2026.118730_bb0025","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1002\/cncr.33587","article-title":"The ever-increasing importance of cancer as a leading cause of premature death worldwide","volume":"127","author":"Bray","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.bmc.2026.118730_bb0030","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA-Cancer J Clin"},{"key":"10.1016\/j.bmc.2026.118730_bb0035","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1186\/s13045-022-01362-9","article-title":"Small-molecule inhibitors, immune checkpoint inhibitors, and more: FDA-approved novel therapeutic drugs for solid tumors from 1991 to 2021","volume":"15","author":"Wu","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.bmc.2026.118730_bb0040","doi-asserted-by":"crossref","first-page":"245","DOI":"10.3389\/fphar.2018.00245","article-title":"Editorial: adverse effects of cancer chemotherapy: anything new to improve tolerance and reduce sequelae?","volume":"9","author":"Nurgali","year":"2018","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.bmc.2026.118730_bb0045","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118730_bb0050","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/d41573-021-00022-w","article-title":"The most successful oncology drug portfolios of the past decade","volume":"20","author":"Paliouras","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.bmc.2026.118730_bb0055","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1038\/s41568-020-00302-4","article-title":"Non-genetic mechanisms of therapeutic resistance in cancer","volume":"20","author":"Marine","year":"2020","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.bmc.2026.118730_bb0060","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1038\/s41586-024-07690-9","article-title":"Cellular adaptation to cancer therapy along a resistance continuum","volume":"631","author":"Franca","year":"2024","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118730_bb0065","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1126\/science.1168243","article-title":"Drug discovery and natural products: end of an era or an endless frontier?","volume":"325","author":"Li","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.bmc.2026.118730_bb0070","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J Nat Prod"},{"key":"10.1016\/j.bmc.2026.118730_bb0075","doi-asserted-by":"crossref","first-page":"6864","DOI":"10.1038\/s41467-024-51285-x","article-title":"The gradual establishment of complex coumarin biosynthetic pathway in Apiaceae","volume":"15","author":"Huang","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.bmc.2026.118730_bb0080","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/35081178","article-title":"Natural products and plant disease resistance","volume":"411","author":"Dixon","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.bmc.2026.118730_bb0085","article-title":"Synthesis and bioactivities of penta-1,4-dien-3-one derivatives containing a coumarin moiety","volume":"44","author":"Wang","year":"2023","journal-title":"Chem J Chin Univ"},{"key":"10.1016\/j.bmc.2026.118730_bb0090","doi-asserted-by":"crossref","unstructured":"Sandhu S, Bansal Y, Silakari O, et al. Coumarin hybrids as novel therapeutic agents. Bioorg Med Chem 2024;22:3806\u20133814. doi:https:\/\/doi.org\/10.1016\/j.bmc.2014.05.032.","DOI":"10.1016\/j.bmc.2014.05.032"},{"key":"10.1016\/j.bmc.2026.118730_bb0095","article-title":"Coumarins and coumarin-related compounds in pharmacotherapy of cancer","volume":"12","author":"Akkol","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.bmc.2026.118730_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2020.104163","article-title":"Recent advancements of coumarin-based anticancer agents: An up-to-date review","volume":"103","author":"Al-Warhi","year":"2020","journal-title":"Bioorg Chem"},{"key":"10.1016\/j.bmc.2026.118730_bb0105","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.ejmech.2018.07.013","article-title":"Novel curcumin analogue hybrids: synthesis and anticancer activity","volume":"156","author":"Wang","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118730_bb0110","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2019.111587","article-title":"Coumarin-containing hybrids and their anticancer activities","volume":"181","author":"Zhang","year":"2019","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118730_bb0115","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ejmech.2018.03.076","article-title":"An overview of quinazolines: pharmacological significance and recent developments","volume":"151","author":"Alagarsamy","year":"2018","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118730_bb0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118538","article-title":"Medicinal chemistry perspective on quinazoline derivatives: sustainable synthetic routes, anticancer evaluation, and SAR analysis","volume":"304","author":"Dutta","year":"2026","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118730_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2023.188967","article-title":"20 years since the approval of first EGFR-TKI, gefitinib: insight and foresight","volume":"1878","author":"Singh","year":"2023","journal-title":"Biochim Biophys Acta Rev Cancer"},{"key":"10.1016\/j.bmc.2026.118730_bb0130","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118497","article-title":"Unveiling the power of quinazoline derivatives: a new frontier in targeted cancer therapy","volume":"133","author":"Long","year":"2026","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2026.118730_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113016","article-title":"Therapeutic progression of quinazolines as targeted chemotherapeutic agents","volume":"211","author":"Bansal","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118730_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.118411","article-title":"Pharmacophore-guided review of EGFR-targeted anticancer drugs with gefitinib as a reference","volume":"303","author":"Meenu","year":"2026","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118730_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112995","article-title":"The new opportunities in medicinal chemistry of fourth-generation EGFR inhibitors to overcome C797S mutation","volume":"210","author":"He","year":"2021","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118730_bb0150","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejmech.2017.07.023","article-title":"How to train your inhibitor: design strategies to overcome resistance to epidermal growth factor receptor inhibitors","volume":"142","author":"Milik","year":"2017","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118730_bb0155","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117268","article-title":"Pyrimidine-based dual-target inhibitors targeting epidermal growth factor receptor for overcoming drug resistance in cancer therapy (2006-present)","volume":"286","author":"An","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118730_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117677","article-title":"Annual review of EGFR inhibitors in 2024","volume":"292","author":"Gao","year":"2025","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmc.2026.118730_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118242","article-title":"An N-linked imidazo[1,2-a]pyridine benzoheterobicyclic hybrid inhibits mitosis and cancer cell proliferation by targeting tubulin","volume":"128","author":"Sarkar","year":"2025","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2026.118730_bb0170","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118089","article-title":"Design, synthesis and biological evaluation of benzo[b]thiophene analogues as novel ferroptosis inhibitor that inhibit fibrosarcoma cell proliferation","volume":"120","author":"Yang","year":"2025","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmc.2026.118730_bb0175","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11030-024-10863-3","article-title":"Design, synthesis, and antitumor activity evaluation of BF3-o,m,p-phenylenediamine bridged with pyrimidine-indole BF3 adduction derivatives","volume":"29","author":"Zhou","year":"2025","journal-title":"Mol Divers"},{"key":"10.1016\/j.bmc.2026.118730_bb0180","doi-asserted-by":"crossref","unstructured":"Stamos J, Sliwkowski MX, Eigenbrot C, et al. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 2002;277:46265\u201346272. doi:https:\/\/doi.org\/10.1074\/jbc.M207135200.","DOI":"10.1074\/jbc.M207135200"},{"key":"10.1016\/j.bmc.2026.118730_bb0185","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.ccr.2006.12.017","article-title":"Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity","volume":"11","author":"Yun","year":"2007","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmc.2026.118730_bb0190","doi-asserted-by":"crossref","first-page":"13165","DOI":"10.1021\/acs.jafc.2c04933","article-title":"Expedient discovery for novel antifungal leads inhibiting fusarium graminearum: 3-(Phenylamino)quinazolin-4(3H)-ones deriving from systematic optimizations on a tryptanthrin structure","volume":"70","author":"Wang","year":"2022","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.bmc.2026.118730_bb0195","article-title":"Novel quinazolin-4(3H)-one bionic-alkaloids bearing an 1,3,4-oxadiazole fragment as potential fungicides inhibiting Botrytis cinerea: design, synthesis and bioactive-guided structural optimization","volume":"17","author":"Wang","year":"2024","journal-title":"Arab J Chem"},{"key":"10.1016\/j.bmc.2026.118730_bb0200","doi-asserted-by":"crossref","first-page":"14426","DOI":"10.1021\/acs.jafc.0c03736","article-title":"Expedient discovery for novel antifungal leads targeting succinate dehydrogenase: Pyrazole-4-formylhydrazide derivatives bearing a diphenyl ether fragment","volume":"68","author":"Wang","year":"2020","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.bmc.2026.118730_bb0205","doi-asserted-by":"crossref","first-page":"9557","DOI":"10.1021\/acs.jafc.1c03399","article-title":"Novel pyrazole-4-acetohydrazide derivatives potentially targeting fungal succinate dehydrogenase: design, synthesis, three-dimensional quantitative structure-activity relationship, and molecular docking","volume":"69","author":"Wang","year":"2021","journal-title":"J Agric Food Chem"},{"key":"10.1016\/j.bmc.2026.118730_bb0210","doi-asserted-by":"crossref","first-page":"11308","DOI":"10.1021\/acs.jafc.3c07880","article-title":"Design, synthesis, antifungal activity, and action mechanism of pyrazole-4-carboxamide derivatives containing oxime ether active fragment as succinate dehydrogenase inhibitors","volume":"72","author":"Chai","year":"2024","journal-title":"J Agric Food Chem"}],"container-title":["Bioorganic & Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001860?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0968089626001860?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T19:18:55Z","timestamp":1783192735000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0968089626001860"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":42,"alternative-id":["S0968089626001860"],"URL":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118730","relation":{},"ISSN":["0968-0896"],"issn-type":[{"value":"0968-0896","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Novel (Z)-3-(2-(quinazolin-4-yloxy)phenyl)acrylates as potential EGFR inhibitors deriving from the renovation of coumarin skeletons: Design, synthesis, characterization and antineoplastic activity","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmc.2026.118730","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118730"}}